Patents show all

11Applications9Issued

Clinical Trials show all

9Phase 22Phase 3

SEC Filings show all

8-K3310-Q1010-K3D3S-11

SEC Form D Funding Events

DateOfferedSoldType
2013-07-09$22,272,848$21,772,848Equity
2009-04-22Indefinite$20,411,559Equity, Option to Acquire
2005-10-12UnknownUnknownOther (Paper Filing)

Key Executives

  • John Krayacich
    Executive Officer, Director
  • Stephen Bloch
    Director
  • Kenneth Shaw
    Executive Officer
  • Alan Barber
    Executive Officer
  • Cable Stuart
    Executive Officer
  • Timothy Mayleben
    Director
  • Anand Mehra
    Director
  • Harry H. Penner, Jr.
    Director
  • Nicole Vitullo
    Director
  • Christopher M. Cashman
    Executive Officer, Director
  • Stephen Bloch, M.D.
    Director
  • Harry T. Rein
    Director
  • Anand Mehra, M.D.
    Director
  • Timothy M. Mayleben
    Director
  • Harry Penner
    Director
  • Anton Gopka
    Director